Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases

Yefroyev, David A; Jin, Sha

doi:10.3390/biomedicines10020208

Cited by 21 publications

(15 citation statements)

References 80 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, numerous studies have demonstrated that iPSCs and ESCs are molecularly and functionally equivalent, avoiding the ethical issues and the constraints of traditional methods. This provides a meaningful solution for a sustainable source of pluripotent stem cells without the need for immunosuppressive agents to combat immune rejection after implantation therapy (Yefroyev and Jin, 2022). Similar to ESCs, iPSCs show selfrenewal ability and multi-directional differentiation potential.…”

Section: Treatment Of Parkinson's Disease Based On the Interaction Of...mentioning

confidence: 99%

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Huang

Zhang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s disease, commonly occurs in the elderly population, causing a significant medical and economic burden to the aging society worldwide. At present, there are few effective methods that achieve satisfactory clinical results in the treatment of PD. Platelet-derived growth factors (PDGFs) and platelet-derived growth factor receptors (PDGFRs) are important neurotrophic factors that are expressed in various cell types. Their unique structures allow for specific binding that can effectively regulate vital functions in the nervous system. In this review, we summarized the possible mechanisms by which PDGFs/PDGFRs regulate the occurrence and development of PD by affecting oxidative stress, mitochondrial function, protein folding and aggregation, Ca2+ homeostasis, and cell neuroinflammation. These modes of action mainly depend on the type and distribution of PDGFs in different nerve cells. We also summarized the possible clinical applications and prospects for PDGF in the treatment of PD, especially in genetic treatment. Recent advances have shown that PDGFs have contradictory roles within the central nervous system (CNS). Although they exert neuroprotective effects through multiple pathways, they are also associated with the disruption of the blood–brain barrier (BBB). Our recommendations based on our findings include further investigation of the contradictory neurotrophic and neurotoxic effects of the PDGFs acting on the CNS.

show abstract

Section: Treatment Of Parkinson's Disease Based On the Interaction Of...mentioning

confidence: 99%

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Huang

Zhang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…A few other recent studies have also expanded our understanding of viral infections and the associated neurological complications. iPSC- derived cells can be used as 2D and 3D cultures for CNS disease modeling, phenotypic assays, neural differentiation analysis, functional characterization, and cell migration studies, as well as cell therapies [ 253 , 254 , 255 , 256 , 257 ]. The potential of 3D brain organoids, derived from iPSCs, to replicate the CNS cell networks, shedding light on infections like HIV-1, HSV-1, and SARS-CoV-2 has been described [ 258 ].…”

Section: The Use Of Ipsc-derived Cells In Neuroinflammatory Disease P...mentioning

confidence: 99%

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders

Cohen,

Mathew,

Dourvetakis

et al. 2024

Cells

View full text Add to dashboard Cite

Neuroinflammatory and neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), traumatic brain injury (TBI) and Amyotrophic lateral sclerosis (ALS) are chronic major health disorders. The exact mechanism of the neuroimmune dysfunctions of these disease pathogeneses is currently not clearly understood. These disorders show dysregulated neuroimmune and inflammatory responses, including activation of neurons, glial cells, and neurovascular unit damage associated with excessive release of proinflammatory cytokines, chemokines, neurotoxic mediators, and infiltration of peripheral immune cells into the brain, as well as entry of inflammatory mediators through damaged neurovascular endothelial cells, blood–brain barrier and tight junction proteins. Activation of glial cells and immune cells leads to the release of many inflammatory and neurotoxic molecules that cause neuroinflammation and neurodegeneration. Gulf War Illness (GWI) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are chronic disorders that are also associated with neuroimmune dysfunctions. Currently, there are no effective disease-modifying therapeutic options available for these diseases. Human induced pluripotent stem cell (iPSC)-derived neurons, astrocytes, microglia, endothelial cells and pericytes are currently used for many disease models for drug discovery. This review highlights certain recent trends in neuroinflammatory responses and iPSC-derived brain cell applications in neuroinflammatory disorders.

show abstract

“…Clinical trials using iPSCs are still rare and not yet being applied in AD, although there are some studies on Parkinson’s disease [ 193 , 194 , 195 , 196 ]. Progress in using stem cells in humans is slowed by the disadvantages, such as the need for immunosuppression and the risk of tumor formation with progenitor cells [ 165 ].…”

Section: Stem Cellsmentioning

confidence: 99%

Alzheimer’s Disease Treatment: The Search for a Breakthrough

et al. 2023

View full text Add to dashboard Cite

As the search for modalities to cure Alzheimer’s disease (AD) has made slow progress, research has now turned to innovative pathways involving neural and peripheral inflammation and neuro-regeneration. Widely used AD treatments provide only symptomatic relief without changing the disease course. The recently FDA-approved anti-amyloid drugs, aducanumab and lecanemab, have demonstrated unclear real-world efficacy with a substantial side effect profile. Interest is growing in targeting the early stages of AD before irreversible pathologic changes so that cognitive function and neuronal viability can be preserved. Neuroinflammation is a fundamental feature of AD that involves complex relationships among cerebral immune cells and pro-inflammatory cytokines, which could be altered pharmacologically by AD therapy. Here, we provide an overview of the manipulations attempted in pre-clinical experiments. These include inhibition of microglial receptors, attenuation of inflammation and enhancement of toxin-clearing autophagy. In addition, modulation of the microbiome-brain-gut axis, dietary changes, and increased mental and physical exercise are under evaluation as ways to optimize brain health. As the scientific and medical communities work together, new solutions may be on the horizon to slow or halt AD progression.

show abstract

Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases

Cited by 21 publications

References 80 publications

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders

Alzheimer’s Disease Treatment: The Search for a Breakthrough

Contact Info

Product

Resources

About